6月3日16:30，仁醫(yī)醫(yī)療三人團(tuán)隊前往海德堡大學(xué)附屬醫(yī)院，拜訪婦產(chǎn)科主任 Zivanovic教授及其團(tuán)隊。教授的助理早早在會議室等候，為我們準(zhǔn)備了咖啡、飲品和甜咸點心，細(xì)致周到。Zivanovic 教授與三位年輕的婦科腫瘤專業(yè)進(jìn)修醫(yī)生一同出席了會談。在我們簡要介紹了仁醫(yī)醫(yī)療的發(fā)展背景與合作模式后，Dr. Herrmann與 Dr. K?hler向我們系統(tǒng)介紹了他們團(tuán)隊的婦科腫瘤?？七M(jìn)修項目。該項目聚焦于婦科惡性腫瘤的臨床與科研能力培養(yǎng)，僅向已完成婦科?？普J(rèn)證的醫(yī)生開放申請。項目總周期為四年：前兩年進(jìn)修醫(yī)生在德國癌癥研究中心（DKFZ）從事科研工作，并參與每周一次的婦科腫瘤多學(xué)科會診；后兩年則在海德堡大學(xué)附屬醫(yī)院的相關(guān)臨床科室輪轉(zhuǎn)，全面提升婦科惡性腫瘤診療能力。Zivanovic教授強調(diào)，這是一個高度專業(yè)化的培訓(xùn)路徑，符合當(dāng)前醫(yī)學(xué)日益“亞專科化”的發(fā)展趨勢。Zivanovic教授自2023年起擔(dān)任海德堡大學(xué)附屬醫(yī)院婦產(chǎn)科主任，加入前曾長期在紐約斯隆·凱特林癌癥研究所執(zhí)業(yè)。他擁有國際化的臨床與科研背景，致力于將先進(jìn)的腫瘤治療理念融入德國婦產(chǎn)科的診療實踐。他所領(lǐng)導(dǎo)的婦科腫瘤中心是德國癌癥學(xué)會認(rèn)證的高水平診療與研究單位，核心關(guān)注卵巢癌、子宮內(nèi)膜癌、宮頸癌等多種婦科惡性腫瘤的個體化治療與綜合管理，強調(diào)精準(zhǔn)醫(yī)療、創(chuàng)新臨床路徑與多學(xué)科合作。在交流中，Zivanovic 教授高度肯定了仁醫(yī)醫(yī)療的理念。他表示，近年來在國際會議上頻頻見到中國同道在婦科腫瘤領(lǐng)域的突出貢獻(xiàn)，但苦于缺乏合適的渠道，難以實現(xiàn)深入交流。他坦言，自己每天都收到不少來自中國學(xué)生、醫(yī)生和研究人員的聯(lián)系請求，但由于數(shù)量龐大、背景各異，確實難以甄別與統(tǒng)籌，因此看到我們這樣的專業(yè)機(jī)構(gòu)介入合作推進(jìn)，讓他感到非常安心與期待。他希望今后能借助仁醫(yī)醫(yī)療與中國開展更直接、更深入的合作交流。

At 16:30 of June 3rd, the team of three from Gloryren went to Heidelberg University Hospital to visit Prof. Zivanovic, Director of the Department of Gynecology and Obstetrics, and his team. Ms. ?nal, Prof. Zivanovic’s assistant, was waiting in the conference room, kindly preparing coffee, other drinks, and some sweet and savory snacks for us. Prof. Zivanovic attended the meeting with three fellows. After our brief introduction to Gloryren's background and cooperation model, Dr. Herrmann and Dr. K?hler provided a detailed presentation on the structured fellowship program for gynecologic oncology. This program focuses on the training of both clinical and research competencies in gynecologic malignancies and is open exclusively to certified specialist in gynecology. The total duration of the program is four years: in the first two years, fellows engage in research at the German Cancer Research Center (DKFZ) and participate in weekly multidisciplinary gynecologic tumor boards; in the last two years, they rotate in relevant clinical departments at Heidelberg University Hospital to comprehensively enhance their diagnostic and treatment skills for gynecologic malignancies. Prof. Zivanovic emphasized that this is a highly specialized training pathway that aligns with the current trend toward increasing "subspecialization" in medicine. Since 2023, Prof. Zivanovic has served as the Director of Gynecology and Obstetrics at Heidelberg University Hospital. Before joining Heidelberg University Hospital, he practiced for many years at Memorial Sloan Kettering Cancer Center in New York. With extensive international clinical and research experience, Prof. Zivanovic is dedicated to integrating advanced oncology treatment concepts into the practice of gynecology in Germany. The Center for Gynecological Cancer led by him is a high-level treatment and research center, certified by the German Cancer Society       (DKG). It focuses on the individualized treatment and comprehensive management of various gynecologic malignancies such as ovarian cancer, endometrial cancer, and cervical cancer, with a strong emphasis on precision medicine, innovative clinical pathways, and multidisciplinary collaboration. During the meeting, Prof. Zivanovic highly acknowledged with the concept of Gloryren. He shared that in recent years, he has repeatedly noticed remarkable contributions from Chinese colleagues in the field of gynecologic oncology at international conferences, but due to the limited access, he found it difficult to have in-depth exchanges with them. Therefore, with the help of a professional institution like Gloryren, he has gained a strong sense of confidence and now holds high expectations for the collaboration. He hopes to establish more direct and in-depth exchanges with China via Gloryren in the future.